As PD-L1 expression in tumours has been described to augment the expression of other immunosuppressive biomarkers such as CX3CR1 at the local tumour microenvironment (45), we also quantified the double expression of PD-L1 and CX3CR1 after SFRE treatment. This evidence concerns the gene CX3CR1 and neoplasm.